Growing Evidence that Anti BRAF Melanoma Drugs Benefit Some Patients with Non-Small Cell Lung Cancer

Growing Evidence that Anti BRAF Melanoma Drugs Benefit Some Patients with Non-Small Cell Lung Cancer

27/04/2015

GENEVA—Findings from the retrospective EURAF study suggest that many patients with BRAF-mutant lung cancers could benefit from treatment with BRAF inhibitors, although specific studies need to be done

GENEVA—Findings from the retrospective EURAF study suggest that many patients with BRAF-mutant lung cancers could benefit from treatment with BRAF inhibitors, although specific studies need to be done to confirm this. Data presented at the European Lung Cancer Conference by Oliver Gautschi MD, a medical oncologist from Lucern Cantonal Hospital, Switzerland, found that off-label use of melanoma medicines targeting BRAF achieved significant response rates in patients with advanced non-small cell lung cancer. He discussed the clinical potential of these drugs in lung cancer with Oncology Times reporter Peter Goodwin.